This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=102 http://www.lsis.com/goto/r102/rss 2012-02-05T11:11:04+01:00 text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 SAN DIEGO-(BUSINESS WIRE)- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) announced that results from the Phase II study of its Captisol-enabled, propylene glycol-free (PG-free) Melphalan program were featured this evening in a poster presentation at the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) in San Diego. The Phase II study was completed in late 2011 (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8105266 |-| Title: Mobile dialysis system having supply container detection |-| Inventors: Childers; Robert W. (Trinity, FL), Roger; Rodolfo (Clearwater, FL) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| A dialysis system includes a dialysis instrument including at least one pump actuator; a disposable cassette operable with the at least one pump actuator; a plurality of supply containers connected fluidly to (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8105258 |-| Title: Citrate anticoagulation system for extracorporeal blood treatments |-| Inventors: Lannoy; Jean-Michel (Anstaing, FR) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8105269 |-| Title: In situ tubing measurements for infusion pumps |-| Inventors: Zhou; Yu (Vernon Hills, IL) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| An infusion pump uses sensors and a computer program to detect tubing in a tube-loading section of the pump. The pump and the computer program also measures one or more of the tubing outer diameter, outer circumference, inner diameter, inner circumference, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. (NYSE:BAX) today announced its financial results for the fourth quarter of 2011, and provided its financial outlook for the first quarter and full-year 2012. Baxter reported net income in the fourth quarter of $463 million, which advanced 9 percent from $423 million reported in the prior-year period. Earnings per diluted share of $0.82 compares to $0.72 per diluted share reported in the fourth quarter of 2010, reflecting an increase (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. (NYSE:BAX) today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] (marketed as KIOVIG outside the United States and Canada), for the treatment of mild to moderate Alzheimer s disease. The company plans to initiate a second, confirmatory Phase III trial in the first quarter of 2012, having satisfactorily completed a futility analysis in its first Phase III trial. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 San Francisco Business Times by Ron Leuty, Reporter When Howard Robin took over as president and CEO of Nektar Therapeutics Inc. . in early 2007, the company was based in San Carlos with a high payroll and, essentially, one product in the form of the inhaled insulin drug-device Exubera. Since Pfizer Inc. . pulled Exubera later that year, Nektar (NASDAQ: NKTR) has moved to San Francisco, shed workers, cut expenses and developed several programs, ranging from breast cancer to pain. I take a (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 Minneapolis / St. Paul Business Journal by Ed Stych, Web Producer Medtronic Inc. has lost the president of its international operations, as Jean-Luc Butel has taken a similar position with competitor Baxter International Inc. Butel, 55, will report to Baxter CEO Robert Parkinson Jr. and will start his new job as president of international operations on Feb. 20, according to a Baxter news release. Parkinson said in a statement that Butel's international experience will help Deerfield, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. (NYSE:BAX) announced today that Jean-Luc Butel has been appointed corporate vice president and president, international, reporting to Robert L. Parkinson, Jr., chairman and chief executive officer. He will assume his new role on February 20, 2012. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8092820 |-| Title: Dry hemostatic compositions and methods for their preparation |-| Inventors: Qian; Zhen (Fremont, CA), Osawa; A. Edward (San Francisco, CA), Reich; Cary J. (Los Gatos, CA) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8093230 |-| Title: Supersaturated aqueous ifosfamide compositions |-| Inventors: Roessler; Berthold (Halle, DE) |-| Assignee: Baxter International Inc. (Deerfield, IL) |-| The invention concerns the use of mercaptoethane sulfonate-sodium (Mesna) to increase the solubility of Ifosfamide in storage-stable, concentrated and/or highly-concentrated (supersaturated) aqueous pharmaceutical preparations, storage-stable, concentrated and/or highly-concentrated (supersaturated) (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for the treatment of multifocal motor neuropathy (MMN). The product, marketed as KIOVIG outside the United States and Canada, was approved for the MMN indication in Europe in 2011. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. (NYSE: BAX) today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein. BAX 855 is based on Baxter s ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] full-length rFVIII molecule and plasma/albumin-free (PAF) manufacturing process. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. (NYSE: BAX) has been notified of an unsolicited œmini-tender  offer by TRC Capital Corporation to purchase up to 2 million shares, or approximately 0.35 percent, of Baxter s outstanding common stock at a price of $46.10 per share in cash. The offer price was 4.67 percent below the $48.36 closing price of Baxter s common stock on December 15, 2011, the day prior to the offer. TRC s offer is subject to a number of conditions, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill. & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Baxter International Inc. (NYSE:BAX) and Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that they have entered into a global collaboration to develop and commercialize follow-on biologic products, also known as biosimilars. Biosimilars replicate existing, branded biologics used in the treatment of a variety of diseases including cancer, autoimmune disorders and other chronic conditions. With this collaboration, Baxter will (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8083677 |-| Title: Access disconnect detection using glucose |-| Inventors: Rohde; Justin B. (Des Plaines, IL) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark ( Opfikon), CH) |-| An access disconnect sensor for a patient undergoing extracorporeal blood processing includes an electrochemical fuel cell or sensor to detect blood leakage. The fuel cell includes circuitry for oxidizing glucose in the blood. The sensor also includes a (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8083709 |-| Title: Dialysis method having supply container autoconnection |-| Inventors: Childers; Robert W. (Trinity, FL), Holmquist; Kurt (Lutz, FL), Hopping; Peter A. (Lutz, FL) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| A method for connecting a plurality of solution line connectors to a plurality of supply line connectors of a dialysis system includes: translating a tip protector remover in a first (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill. & CAMBRIDGE, Mass., Dec. 22, 2011 - Baxter International Inc. (NYSE:BAX - News) and Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA - News) today announced that they have entered into a global collaboration to develop and commercialize follow-on biologic products, also known as biosimilars. Biosimilars replicate existing, branded biologics used in the treatment of a variety of diseases including cancer, autoimmune disorders and other chronic conditions. With this collaboration, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. (NYSE: BAX) announced today that it will present at the 30th Annual J.P. Morgan Health Care Conference on Tuesday, January 10, 2012, at 2:30 p.m. (PT) or 5:30 p.m. (ET). The live webcast of Baxter s presentation can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through February 9, 2012. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 SAN DIEGO-(BUSINESS WIRE)-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has entered into platform Captisol license and supply agreements with Eli Lilly and Company in undisclosed therapeutic areas. During the collaboration, Lilly will be permitted to nominate an unlimited number of drug candidates from its internal pipeline for Captisol formulation. Ligand will provide clinical supplies of Captisol, and may ultimately supply commercial quantities of Captisol to (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 PLAINSBORO, N.J., Dec. 21, 2011 (GLOBE NEWSWIRE) - Integra LifeSciences Holdings Corporation (Nasdaq:IART - News) announced today that its Board of Directors has made the following changes, all effective January 3, 2012. The Board appointed Peter Arduini as President and Chief Executive Officer. In addition, the Board elected Mr. Arduini to a newly-created position on the Board. Stuart Essig has been appointed as Executive Chairman of the Board. Richard Caruso, founder of Integra LifeSciences (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A. ADVATE is the only antihemophilic factor approved in the United States for prophylactic use in both adults and children. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. (NYSE: BAX) demonstrated its commitment to volunteerism and product donation as well as to environmentally-conscious practices and corporate social responsibility through several recent initiatives and recognition. Baxter employees in the Asia Pacific region mobilized for a month of volunteering and giving back in their communities, and also responded quickly to the urgent need for peritoneal dialysis therapy and intravenous solutions (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 ST. PAUL, Minn.-(BUSINESS WIRE)-Synovis Life Technologies, Inc. (Nasdaq: SYNO), today reported its financial results for the fourth quarter and fiscal year ended October 31, 2011. Yesterday, Synovis and Baxter International Inc., (NYSE:BAX) announced a definitive agreement for Baxter to acquire Synovis. The Synovis board of directors has unanimously approved the transaction and recommends that shareholders approve the agreement at an offer price of $28 per share, which equates to $325 (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill. & ST. PAUL, Minn.-(BUSINESS WIRE)-Baxter International Inc. (NYSE:BAX) and Synovis Life Technologies, Inc. (NASDAQ:SYNO) today announced a definitive agreement for Baxter to acquire Synovis, a leading provider of biological and mechanical products for soft tissue repair used in a variety of surgical procedures. The acquisition complements and will expand the portfolio of Baxter s regenerative medicine and biosurgery franchise, which includes a number of devices and biological (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8075526 |-| Title: Automated dialysis system including a piston and vacuum source |-| Inventors: Busby; Don (Tampa, FL), Childers; Robert (New Port Richey, FL) |-| Assignee: Baxter International Inc. (Deerfield, IL) |-| A peritoneal dialysis system includes a hardware unit including a piston and at least one vacuum source; a door connected to the hardware unit, the door including a cavity, the cavity having a diameter; the hardware unit further including a structure (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8075544 |-| Title: Containers and methods for manufacturing same |-| Inventors: Peluso; Francesco (Heverlee, BE), Anders; Tranaeus (Shangai, CN), Faict; Dirk (Assenede, BE), Balteau; Patrick R. (Evelette, BE), Gollier; Paul-Andre (Waterloo, BE), Dewez; Jean-Luc (Bousval, BE), Henaut; Eric J. (Arquennes, BE), Houwaert; Vincent (Celles, BE), Lambert; Philippe (Wezembeek-Oppem, BE) |-| Assignee: Baxter International Inc. (Deerfield, IL) |-| A container is provided comprising (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8075919 |-| Title: Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |-| Inventors: Brown; Larry (Newton, MA), McGeehan; John K. (Woodbury, NJ), Rashba-Step; Julia (Newton, MA), Scott; Terrence L. (Winchester, MA) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Wallisellen, CH) |-| The present invention is related to a method for preparing small spherical particles of an (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8076463 |-| Title: Polymer-von Willebrand factor-conjugates |-| Inventors: Scheiflinger; Friedrich (Vienna, AT), Turecek; Peter (Klosterneuburg, AT), Siekmann; Juergen (Vienna, AT) |-| Assignee: Baxter International, Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glatttpark (Opfikon), CH) |-| The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8071728 |-| Title: Factor VIII polymer conjugates |-| Inventors: Turecek; Peter (Klosterneuburg, AT), Siekmann; Juergen (Vienna, AT) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8071725 |-| Title: Factor VIII polymer conjugates |-| Inventors: Turecek; Peter (Klosterneuburg, AT), Siekmann; Juergen (Vienna, AT) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8071727 |-| Title: Factor VIII polymer conjugates |-| Inventors: Turecek; Peter (Klosterneuburg, AT), Siekmann; Juergen (Vienna, AT) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8071726 |-| Title: Factor VIII polymer conjugates |-| Inventors: Turecek; Peter (Klosterneuburg, AT), Siekmann; Juergen (Vienna, AT) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8071724 |-| Title: Factor VIII polymer conjugates |-| Inventors: Turecek; Peter (Klosterneuburg, AT), Siekmann; Juergen (Vienna, AT) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8070709 |-| Title: Peritoneal dialysis machine |-| Inventors: Childers; Robert W. (Trinity, FL) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| A peritoneal dialysis machine including: a housing; a mechanically actuated piston head extending from a pump actuator housed by the housing, the mechanically actuated piston head positioned to extend towards and away from a fluid pumping cassette, the fluid pumping (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8067543 |-| Title: Factor VIII polymer conjugates |-| Inventors: Turecek; Peter (Klosterneuburg, AT), Siekmann; Juergen (Vienna, AT) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. (NYSE: BAX) announced today that it will present at the 23rd Annual Piper Jaffray Health Care Conference on Tuesday, November 29, 2011, at 12:00 p.m. (CT) or 1:00 p.m. (ET). text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.335 per Baxter common share, payable on January 4, 2012 to shareholders of record as of the close of business on December 9, 2011. This represents an annual dividend rate of $1.34 per share, and an increase of approximately 8 percent over the previous annual rate of $1.24. text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. (NYSE:BAX) announced today that the company has completed its planned acquisition of Baxa Corporation, a privately held global company based in Englewood, Colo., for a cash consideration of $380 million. Baxa develops pharmacy technology that enhances the efficiency and safety of oral and IV dose preparation and delivery. œThe acquisition of Baxa demonstrates Baxter s long-term commitment to nutrition and patient safety and it allows (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. (NYSE:BAX) announced today that the company has completed its planned acquisition of Baxa Corporation, a privately held global company based in Englewood, Colo., for a cash consideration of $380 million. Baxa develops pharmacy technology that enhances the efficiency and safety of oral and IV dose preparation and delivery. text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=102 SAN DIEGO-(BUSINESS WIRE)-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (the œCompany  or œLigand ) today announced financial results for the three and nine months ended September 30, 2011 and provided a business update. In addition to these programs, many others are advancing toward potential revenue generation for Ligand. In the past quarter, we announced new licensing transactions with Chiva Pharmaceuticals for Fablyn and with Sage Pharmaceuticals for a platform Captisol (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8053200 |-| Title: Monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products |-| Inventors: Poole; Stephen (London, GB), Patel; Mehul (Lafayette, CO) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) National Institute for Biological Standards and Control (Blanche Lane, South Mimms, Potters Bar, unknown) |-| An improved monocyte activation test is described that is better (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=102 United States Patent: 8053561 |-| Title: Pegylated factor VIII |-| Inventors: Siekmann; Juergen (Vienna, AT), Varadi; Katalin (Vienna, AT), Gritsch; Herbert (Vienna, AT), Turecek; Peter (Klosterneuburg, AT) |-| Assignee: Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH) |-| The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=102 SAN DIEGO-(BUSINESS WIRE)-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that data from preclinical studies on its Interleukin-1 Receptor Associated Kinase-4 (IRAK4) program was featured in an oral presentation today at the 2011 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP) in Chicago. IRAK4 is a protein kinase involved in immune and inflammatory signaling and has become a high (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=102 SAN DIEGO-(BUSINESS WIRE)-Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that it will host a panel discussion in San Francisco, on Monday, November 7, 2011 to review and discuss the Promacta Phase III ENABLE 1 study results. The ENABLE 1 data will be presented earlier in the day during the Late-Breaking Abstract Session at the American Association for the Study of Liver Disease (AASLD) annual meeting. The event will feature a data review by Nezam Afdhal, M.D. Chief of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=102 BOSTON-(BUSINESS WIRE)-Baxter International Inc. (NYSE: BAX) today announced the presentation of its phase III study data for HyQ, an investigational combination immunoglobulin (IG) product for use in patients with primary immunodeficiencies (PI). The study evaluated efficacy and safety as well as the pharmacokinetics, infusion volumes, intervals, and rates compared to patients previous intravenous immunoglobulin (IGIV) administration. Results from the study were presented on Saturday, Nov. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 BOSTON-(BUSINESS WIRE)-Baxter International Inc. (NYSE: BAX) today announced the presentation of its phase III study data for HyQ, an investigational combination immunoglobulin (IG) product for use in patients with primary immunodeficiencies (PI). The study evaluated efficacy and safety as well as the pharmacokinetics, infusion volumes, intervals, and rates compared to patients previous intravenous immunoglobulin (IGIV) administration. Results from the study were presented on Saturday, Nov. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=102 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/49a1d8/drug_delivery_devi) has announced the addition of the "Drug Delivery Device Market to 2017 - Metered Dose Inhalers and Infusion Pumps to be Key Revenue Generators" report to their offering. Drug Delivery Device Market to 2017 - Metered Dose Inhalers and Infusion Pumps to be Key Revenue Generators Drug Delivery Device Market to 2017 - Metered Dose Inhalers and Infusion Pumps to be Key Revenue (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=102 HANOVER, Germany-(BUSINESS WIRE)-Baxter International Inc. (NYSE:BAX) announced today the European launch of NUMETA (emulsion for infusion). NUMETA was introduced at the 22nd Annual European Society of Pediatric and Neonatal Intensive Care (ESPNIC) Medical and Nursing Annual Congress in Hanover, Germany, as the first and only triple-chamber system with formulations specifically designed to meet the range of intravenous (IV) nutritional requirements of neonatal and pediatric patients (preterm (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=102 HANOVER, Germany-(BUSINESS WIRE)-Baxter International Inc. (NYSE:BAX) announced today the European launch of NUMETA (emulsion for infusion). NUMETA was introduced at the 22nd Annual European Society of Pediatric and Neonatal Intensive Care (ESPNIC) Medical and Nursing Annual Congress in Hanover, Germany, as the first and only triple-chamber system with formulations specifically designed to meet the range of intravenous (IV) nutritional requirements of neonatal and pediatric patients (preterm (…)